Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

0.4723
-0.0057-1.19%
Post-market: 0.47650.0042+0.89%19:30 EDT
Volume:3.91M
Turnover:1.83M
Market Cap:131.30M
PE:-0.95
High:0.4799
Open:0.4792
Low:0.4600
Close:0.4780
52wk High:1.97
52wk Low:0.4600
Shares:278.00M
Float Shares:245.00M
Volume Ratio:0.79
T/O Rate:1.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4975
EPS(LYR):-0.2582
ROE:-547.87%
ROA:-49.87%
PB:4.20
PE(LYR):-1.83

Loading ...

BTIG Remains a Buy on Humacyte (HUMA)

TIPRANKS
·
Jun 24

Piper Sandler Sticks to Its Hold Rating for Humacyte (HUMA)

TIPRANKS
·
Jun 18

Analysts Offer Insights on Healthcare Companies: Humacyte (HUMA) and Qiagen (QGEN)

TIPRANKS
·
Jun 17

U.S. RESEARCH ROUNDUP-CF Industries, Kimberly-Clark, Welltower

Reuters
·
Jun 17

Humacyte Inc : TD Cowen Cuts Target Price to $1.25 From $1.5

THOMSON REUTERS
·
Jun 17

Humacyte Price Target Maintained With a $2.00/Share by BTIG

Dow Jones
·
Jun 16

Humacyte says Phase 3 study shows bioengineered ATEV blood vessel beats AV fistula in women on dialysis

Reuters
·
Jun 15

Humacyte - Enters Underwriting Agreement for Underwritten Offering on June 10, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 12

Humacyte Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jun 11

Humacyte, Inc. : H.c. Wainwright Raises Target Price to $4 From $3

THOMSON REUTERS
·
Jun 11

BUZZ-U.S. STOCKS ON THE MOVE-Enliven Therapeutics, DXC Technology, Humacyte

Reuters
·
Jun 11

U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle

Reuters
·
Jun 11

Humacyte prices 47,619,048-share follow-on offering at $1.05 each to raise $50 million

Reuters
·
Jun 11

Humacyte - Prices Public Offering of 47.62 Mln Shares at $1.05 per Share

THOMSON REUTERS
·
Jun 11

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

GlobeNewswire
·
Jun 11

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

Dow Jones
·
Jun 11

Humacyte's Bioengineered Blood Vessel Hits Primary Endpoint in Phase 3 Trial

Dow Jones
·
Jun 11

Humacyte Says ATEV Met Late-Stage Study Endpoint in Interim Analysis, Launches Public Offering; Shares Fall

MT Newswires Live
·
Jun 11

BRIEF-Humacyte, Inc. Announces Proposed Public Offering Of Common Stock

Reuters
·
Jun 11

Humacyte announces V012 study of ATEV meets primary endpoint

TIPRANKS
·
Jun 11